Last reviewed · How we verify
NCT02541084
Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
trial testing Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) in Wet Macular Degeneration in 72 participants. Completed in 30 July 2016.
30 March 2016
Quick facts
| Lead sponsor | Bayer |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 72 |
| Start date | 18 August 2015 |
| Primary completion | 30 March 2016 |
| Estimated completion | 30 July 2016 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) — full drug profile →
Conditions studied
- Wet Macular Degeneration — all drugs for Wet Macular Degeneration →
Sponsor
Bayer — full company profile →
Who can join
Eligibility, any sex, with Wet Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to proactive therapy especially in real-life rural settings where public transportations are not readily available.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The impact of different anti-vascular endothelial growth factor treatment regimens on reducing burden for caregivers and patients with wet age-related macular degeneration in a single-center real-world Japanese setting.
Hanemoto T, Hikichi Y, Kikuchi N, Kozawa T. · · 2017 · cited 31× · PMID 29220371 · DOI 10.1371/journal.pone.0189035
Verify or expand the search:
- PubMed search for NCT02541084
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Trials testing the same drug.
- NCT05511038 — A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participant · Phase 4 · completed
- NCT04524910 — A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vess · completed
- NCT04641234 — A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-relat · completed
- NCT02818998 — Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME) · Phase 3 · completed
- NCT02811692 — Study for Collection of Aflibercept Data in Routine Practice · completed
Other recruiting trials for Wet Macular Degeneration
Currently open trials in the same condition.
- NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
Other Bayer trials
Trials by the same sponsor.
- NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
- NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
- NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02541084 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bayer
- Last refreshed: 22 August 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02541084.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing